Table 1 Baseline demographics and clinicopathological characteristics of all patients (metastatic and non-metastatic groups)
From: Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study
Characteristic | All patients(N = 1160, 100%) Number (%) | Non-metastatic(N = 844, 72.8%) Number (%) | Metastatic(N = 316, 27.2%) Number (%) | p value |
|---|---|---|---|---|
Age (years) | 0.011* | |||
≤ 10 | 242 (20.9%) | 197 (23.3%) | 45 (14.2%) | |
11–20 | 571 (49.2%) | 402 (47.6%) | 169 (53.5%) | |
21–30 | 206 (17.8%) | 142 (16.8%) | 64 (20.3%) | |
31-49 | 101 (8.7%) | 76 (9.0%) | 25 (7.9%) | |
≥ 50 | 40 (3.4%) | 27 (3.2%) | 13 (4.1%) | |
Gender | 0.926 | |||
Male | 733 (63.2%) | 534 (63.3%) | 199 (63.0%) | |
Female | 427 (36.8%) | 310 (36.7%) | 117 (37.0%) | |
Race | 0.749 | |||
White | 1041 (89.7%) | 759 (89.9%) | 282 (89.2%) | |
Black | 30 (2.6%) | 20 (2.4%) | 10 (3.2%) | |
Other* | 89 (7.7%) | 65 (7.7%) | 24 (7.6%) | |
Primary site | < 0.001*** | |||
Limb | 519 (44.7%) | 405 (48.0%) | 114 (36.1%) | |
Cranial | 66 (5.7%) | 60 (7.1%) | 6 (1.9%) | |
Spine | 88 (7.6%) | 71 (8.4%) | 17 (5.4%) | |
Thoracic | 173 (14.9%) | 129 (15.3%) | 44 (13.9%) | |
Pelvic | 314 (27.1%) | 179 (21.2%) | 135 (42.7%) | |
Tumor size (cm) | < 0.001*** | |||
< 5 | 221 (19.1%) | 185 (21.9%) | 36 (11.4%) | |
5–8 | 371 (32.0%) | 283 (33.5%) | 88 (27.8%) | |
> 8 | 568 (49.0%) | 376 (44.5%) | 192 (60.8%) | |
Tumor extent | - | |||
Localized | 311 (26.8%) | 311 (36.8%) | 0 (0.0%) | |
Regional | 533 (45.9%) | 533 (63.2%) | 0 (0.0%) | |
Metastatic | 316 (27.2%) | 0 (0.0%) | 316 (100.0%) | |
Cancer-directed surgery | < 0.001*** | |||
No | 390 (33.6%) | 213 (25.2%) | 177 (54.0%) | |
Yes | 770 (66.4%) | 631 (74.8%) | 139 (44.0%) | |
Radiation | < 0.001*** | |||
No | 584 (50.3%) | 468 (55.5%) | 116 (36.7%) | |
Yes | 576 (49.7%) | 376 (44.5%) | 200 (63.3%) | |
Chemotherapy | 0.49 | |||
No | 40 (3.4%) | 31 (3.7%) | 9 (2.8%) | |
Yes | 1120 (96.6%) | 813 (96.3%) | 307 (97.2%) |